You are here: Industry Insights > Janssen

News List

EMA approves fourth Covid-19 vaccine, J&J’s single-shot candidate pharmaceutical-technology
March 12, 2021
The European Medicines Agency (EMA) has recommended conditional marketing authorisation for Johnson & Johnson (J&J) subsidiary Janssen’s Covid-19 vaccine.
J&J gets positive CHMP opinion for single-shot COVID-19 vaccine candidate expresspharma
March 12, 2021
If granted conditional marketing authorisation by the EC, the J&J single-shot COVID-19 vaccine will be available in the EU.
Johnson & Johnson announces aingle-ahot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 ENSEMBLE trial worldpharmanews
March 09, 2021
Johnson & Johnson announced top line efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key ...
Health Canada authorises J&J’s Covid-19 vaccine for emergency use pharmaceutical-technology
March 09, 2021
Health Canada has authorised an Interim Order (IO) to the Janssen Pharmaceutical (JPI) Companies of Johnson & Johnson’s (J&J) single-shot vaccine preventing Covid-19 for people aged 18 above.
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine americanpharmaceuticalreview
March 02, 2021
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
FDA authorises emergency use of Janssen’s single shot Covid-19 vaccine pharmaceutical-technology
March 02, 2021
The US Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to the Janssen Pharmaceutical Companies of Johnson & Johnson’s single-dose Covid-19 vaccine.
J&J Announces Single-Shot Janssen COVID-19 Vaccine Candidate Submission to WHO americanpharmaceuticalreview
February 23, 2021
Johnson & Johnson announced Janssen-Cilag International has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate.
Janssen-Cilag seeks EMA authorisation for Covid-19 vaccine candidate pharmaceutical-technology
February 19, 2021
Johnson & Johnson’s (J&J) Janssen-Cilag International has announced it applied to the European Medicines Agency (EMA) to obtain authorisation for its Covid-19 vaccine candidate.
Erleada drug combination extends progression-free survival in prostate cancer trial europeanpharmaceuticalreview
February 10, 2021
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
EU approves expanded use of Janssen’s Spravato pharmatimes
February 09, 2021
The European Commission (EC) has approved the expanded use of Janssen’s Spravato for the rapid reduction of depressive symptoms in a psychiatric emergency, for adult patients with a moderate-to-severe episode of major depressive disorder (MDD).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page